Zai Lab Limited - American Depositary Shares (OQ:ZLAB)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Apr 15, 2024 07:30 am ET

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Wednesday, May 8, 2024. The Company will host a live conference call and webcast on Thursday, May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT).

Apr 11, 2024 07:30 am ET

Zai Lab Statement on Executive Management Team’s Agreement on Share Activities

The Executive Officers of Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, today announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting of equity awards.

Apr 02, 2024 07:30 am ET

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.

Apr 01, 2024 07:30 am ET

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRA

“We are delighted to see these data underscoring the potential of adagrasib as a therapy for patients with KRASG12C mutated NSCLC in second or later line treatment,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, Zai Lab. “Lung cancer is the most common cancer in China, and adagrasib is one of several important products in Zai Lab’s growing lung cancer pipeline. We are proud to have contributed to the KRYSTAL-12 study and are looking forward to bringing adagrasib to patients in need in China."

Mar 27, 2024 09:29 am ET

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me

Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) partner Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer (NSCLC) following stereotactic radiosurgery (SRS). Patients treated with TTFields therapy and supportive care exhibited a median time to intracra

Mar 13, 2024 07:05 pm ET

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from preclinical studies highlighting the therapeutic potential of ZL-1310, the company’s global next-generation antibody-drug conjugate (ADC) program. The preclinical profile of ZL-1310 will be the focus of a poster presentation at the European Lung Cancer Congress 2024 (ELCC 2024), scheduled for March 20-23, 2024 in Prague, Czech Republic.

Mar 06, 2024 04:01 pm ET

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the final overall survival (OS) data from the Phase 3 randomized, double-blind, placebo-controlled NORA study evaluating ZEJULA® (niraparib) in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC) will be shared in oral presentations at the 2024 Congress of the European Society of Gynaecological Oncology (ESGO), March 7-10, 2024, in Barcelona, Spain, and the 2024 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, taking place March 16-18, 2024, in San Diego, CA.

Mar 06, 2024 07:30 am ET

Zai Lab Announces Participation in March Investor Conference

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in March 2024:

Feb 27, 2024 04:05 pm ET

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for full-year 2023, along with recent product highlights and corporate updates.

Jan 25, 2024 04:15 pm ET

Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the year ended December 31, 2023 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, February 27, 2024. The Company will host a live conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET (9:00 p.m. HKT).

Jan 10, 2024 05:12 pm ET

Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced The New England Journal of Medicine (NEJM) has published data from the registrational Phase 1/2 TRIDENT-1 study evaluating repotrectinib (TPX-0005) in patients with ROS1 fusion-positive (RO

Dec 21, 2023 08:31 am ET

Thinking about trading options or stock in Zai Lab, Visa, Crowdstrike, Bristol-Myers Squibb, or Immunovant?

NEW YORK, Dec. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZLAB, V, CRWD, BMY, and IMVT.

Dec 19, 2023 07:30 am ET

Zai Lab Announces Participation in January Investor Conference

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024:

Dec 13, 2023 08:53 am ET

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List

Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced that China’s National Healthcare...

Dec 12, 2023 11:10 pm ET

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications:

Nov 07, 2023 04:05 pm ET

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2023, along with recent product highlights and corporate updates. “During the third quarter, we achieved important milestones, including the...

Oct 26, 2023 07:30 am ET

Zai Lab Announces Participation in November Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023: Jefferies London Healthcare ConferenceFireside Chat:...

Oct 18, 2023 07:30 am ET

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on November 7, 2023. The Company will host a...

Sep 18, 2023 07:30 am ET

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous...

Aug 30, 2023 07:30 am ET

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China

Aug 29, 2023 07:38 am ET

Zai Lab Announces Participation in September Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company’s senior management team will participate in the following investor conferences in September 2023: Citi's 18th Annual BioPharma ConferencePanel Discussion:...

Aug 25, 2023 05:00 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Aug 07, 2023 04:05 pm ET

Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2023, along with recent product highlights and corporate updates. “In the second quarter of 2023, we continued to successfully execute across...

Aug 06, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Bowlero, and Chegg and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zai Lab Limited (NASDAQ: ZLAB), Bowlero Corp. (NYSE: BOWL), and Chegg, Inc. (NYSE: CHGG). Our investigations concern whether...

Aug 05, 2023 07:00 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ: ZLAB) for violations of the securities laws.

Aug 02, 2023 06:00 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Aug 01, 2023 04:00 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jul 26, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Xponential Fitness, Inc. (NYSE: XPOF), Franchise Group, Inc. (NASDAQ: FRG), Zai Lab Limited (NASDAQ: ZLAB), and Alvotech SA...

Jul 25, 2023 06:00 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jul 21, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Jul 20, 2023 07:30 am ET

Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the second quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on August 7, 2023. The Company will host a...

Jul 19, 2023 04:30 pm ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jul 19, 2023 07:30 am ET

JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that JAMA Oncology published data from the pivotal Phase 3 PRIME study evaluating ZEJULA® (niraparib) as a first-line maintenance therapy in Chinese patients with newly diagnosed advanced...

Jul 17, 2023 06:00 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jul 17, 2023 01:03 am ET

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx SE (Euronext & Nasdaq: ARGX) today announced positive topline results from the ADHERE study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic...

Jul 16, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Jul 14, 2023 07:30 am ET

Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been treated in the mainland China portion of the global registrational, Phase 3 FORTITUDE-101 study for bemarituzumab, a potential first-in-class Fc-optimized...

Jul 13, 2023 07:00 am ET

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jul 12, 2023 02:04 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK, July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jul 11, 2023 07:00 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jul 10, 2023 09:39 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Jul 10, 2023 07:30 am ET

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous (SC) injection, 1000mg...

Jul 10, 2023 07:00 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ: ZLAB) for violations of the securities laws.

Jul 09, 2023 01:24 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...

Jul 06, 2023 04:05 pm ET

Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the promotion of Yajing Chen to Chief Financial Officer (CFO), effective July 7, 2023. Dr. Chen, currently Zai Lab’s Deputy CFO based in Cambridge, MA, has been supporting the Company’s...

Jul 06, 2023 06:00 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jul 05, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Xponential Fitness, Inc. (NYSE: XPOF), Franchise Group, Inc. (NASDAQ: ZLAB), Zai Lab Limited (NASDAQ: ZLAB), and Alvotech SA...

Jul 03, 2023 11:55 pm ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jul 03, 2023 05:00 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK, July 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jul 03, 2023 02:00 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

Jul 02, 2023 12:35 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

Jul 01, 2023 02:30 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ: ZLAB) for violations of the securities laws.

Jul 01, 2023 10:36 am ET

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation – ZLAB

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially...

Jun 30, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Hayward and Encourages Investors to Contact the Firm

Jun 30, 2023 04:06 pm ET

ROSEN, A TOP RANKED LAW FIRM, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB

NEW YORK, June 30, 2023 /PRNewswire/ --

Jun 30, 2023 09:22 am ET

Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for VYVGART® (efgartigimod alfa...

Jun 28, 2023 07:30 am ET

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for repotrectinib for the treatment of adult patients with locally advanced or...

Jun 26, 2023 12:50 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 26, 2023 05:45 am ET

ZLAB ALERT: The Law Offices of Vincent Wong Investigate Zai Lab Limited for Potential Violations of Securities Laws

NEW YORK, June 26, 2023 /PRNewswire/ -- Attention Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB) shareholders:

Jun 25, 2023 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zai Lab Limited (Zai Lab Limited), Hayward Holdings, Inc. (NYSE: HAYW), Ascendis Pharma A/S (NASDAQ: ASND), and Alvotech SA...

Jun 25, 2023 08:58 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

Jun 25, 2023 04:19 pm ET

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation – ZLAB

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading...

Jun 23, 2023 11:30 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK , June 23, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jun 23, 2023 05:45 am ET

ZLAB FRAUD ALERT: Jakubowitz Law is Investigating Zai Lab Limited in Connection with Potential Violations of Federal Securities Laws

NEW YORK, June 23, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB)

Jun 22, 2023 06:00 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 22, 2023 05:45 am ET

ZLAB INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Zai Lab Limited

NEW YORK, June 22, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB) concerning possible violations of federal securities laws.

Jun 21, 2023 11:01 pm ET

ZAI LAB ALERT: Bragar Eagel & Squire, P.C. is Investigating Zai Lab Limited on Behalf of Zai Lab Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB) on behalf of Zai Lab stockholders. Our investigation concerns whether Zai Lab has violated the federal securities laws and/or engaged in other unlawful business practices.

Jun 21, 2023 06:00 am ET

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 21, 2023 05:45 am ET

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Zai Lab Limited of an Investigation and Potential Class Action Lawsuit - (NASDAQ: ZLAB)

NEW YORK, June 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zai Lab Limited:

Jun 20, 2023 04:17 pm ET

ZLAB NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Zai Lab Limited

NEW YORK, June 20, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB) violated federal securities laws.

Jun 18, 2023 07:20 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 17, 2023 01:19 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

Jun 17, 2023 11:00 am ET

ROSEN, A LEADING LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB

NEW YORK, June 17, 2023 /PRNewswire/ --

Jun 17, 2023 07:45 am ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

CONTACT:The Schall Law FirmBrian Schall, [email protected]

Jun 15, 2023 07:06 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK, June 15, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jun 15, 2023 09:31 am ET

Thinking about trading options or stock in Plug Power, Microvision, Beigene, Zai Lab, or NVIDIA?

NEW YORK, June 15, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLUG, MVIS, BGNE, ZLAB, and NVDA.

Jun 15, 2023 06:00 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 14, 2023 11:07 am ET

ZLAB INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB

Jun 14, 2023 07:00 am ET

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 13, 2023 07:00 am ET

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 12, 2023 10:00 pm ET

ZLAB INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB

NEW YORK, June 12, 2023 /PRNewswire/ --

Jun 12, 2023 09:36 pm ET

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Zai Lab Limited of an Investigation and Potential Class Action Lawsuit - (NASDAQ: ZLAB)

NEW YORK, June 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zai Lab Limited:

Jun 12, 2023 08:45 pm ET

ZLAB FRAUD ALERT: Jakubowitz Law is Investigating Zai Lab Limited in Connection with Potential Violations of Federal Securities Laws

NEW YORK, June 12, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB).

Jun 12, 2023 08:34 pm ET

ZLAB ALERT: The Law Offices of Vincent Wong Investigate Zai Lab Limited for Potential Violations of Securities Laws

NEW YORK, June 12, 2023 /PRNewswire/ -- Attention Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB) shareholders:

Jun 12, 2023 08:27 pm ET

ZLAB NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Zai Lab Limited

NEW YORK, June 12, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB) violated federal securities laws.

Jun 12, 2023 08:23 pm ET

ZLAB INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Zai Lab Limited

NEW YORK, June 12, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB) concerning possible violations of federal securities laws.

Jun 12, 2023 11:15 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 10, 2023 11:20 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ: ZLAB) for violations of the securities laws.

Jun 09, 2023 01:45 am ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ: ZLAB) for violations of the securities laws.

Jun 08, 2023 01:02 pm ET

EQUITY ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB

Jun 08, 2023 06:00 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws.

Jun 07, 2023 06:42 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zai Lab Limited – ZLAB

Jun 07, 2023 09:00 am ET

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ:

Jun 06, 2023 02:19 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ:

Jun 06, 2023 08:05 am ET

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lu

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) today are presenting positive results from the phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard therapies for...

Jun 01, 2023 04:03 pm ET

Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present three poster presentations with new data, including preliminary results from a clinical study evaluating its internal oncology research and development program ZL-1211, at the 2023 American...

May 25, 2023 07:30 am ET

Zai Lab Announces Participation in June Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company’s senior management team will participate in the following investor conferences in June 2023: Jefferies Global Healthcare ConferenceFireside Chat: Friday, June...

May 18, 2023 07:30 am ET

Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted priority review to repotrectinib for the treatment of adult patients with...

May 09, 2023 04:01 pm ET

Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2023, along with recent product highlights and corporate updates. “Our first quarter results and progress continue to demonstrate Zai Lab’s...

Apr 27, 2023 07:30 am ET

Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics (MediLink). MediLink is an innovative drug development company focusing on next generation...

Apr 26, 2023 10:25 am ET

Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology...

Apr 20, 2023 07:30 am ET

Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2023 and recent corporate updates after the closing of the U.S. equity markets on May 9, 2023. The Company will host a live...

Apr 11, 2023 08:03 am ET

Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data including a translational and biomarker data analysis from its internal oncology discovery program ZL-1211 at the upcoming 2023 American Association for Cancer Research (AACR) Annual...

Mar 20, 2023 06:35 am ET

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p5%) were nausea, dyspepsia, vomiting, constipation, headache, hypertension, diarrhea,...

Mar 01, 2023 04:01 pm ET

Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced full-year 2022 financial results, along with recent product highlights and corporate updates. “In 2022, our four marketed products each had substantial sales growth,...

Feb 28, 2023 07:30 am ET

Zai Lab Announces Participation in March Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in March 2023: Jefferies 2023 Biotech on the Bay SummitPanel Discussion:...

Feb 22, 2023 04:30 pm ET

Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present two oral presentations highlighting the ad hoc interim overall survival (OS) study results of ZEJULA® (niraparib) from the NORA Phase 3 study and a post hoc analysis from the Phase 3 PRIME...

Feb 22, 2023 07:30 am ET

Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR), an investigational drug that combines...

Feb 09, 2023 07:30 am ET

Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that it will report financial results and corporate updates for the twelve months ended December 31, 2022, after the closing of the U.S. equity markets on March 1, 2023. The Company will...

Jan 31, 2023 07:30 am ET

Zai Lab Announces Participation in February Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in the following investor conferences in February 2023: Guggenheim Oncology ConferenceFireside Chat: Wednesday,...

Jan 30, 2023 07:30 am ET

Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA

Jan 18, 2023 07:49 am ET

Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security...

Jan 09, 2023 07:30 am ET

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the...

Jan 05, 2023 07:47 am ET

Thinking about buying stock in Novocure, Zai Lab, Kala Pharmaceuticals, Orchard Therapeutics, or CytomX Therapeutics?

NEW YORK, Jan. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVCR, ZLAB, KALA, ORTX, and CTMX.

Jan 05, 2023 07:34 am ET

Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard...

Jan 03, 2023 08:30 am ET

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development,...

Dec 20, 2022 07:30 am ET

Zai Lab Announces Participation in January Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that senior management from Zai Lab will participate in the following investor conferences in January...

Dec 15, 2022 04:05 pm ET

Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today presented new interim overall survival (OS) data in Chinese patients with platinum-sensitive recurrent ovarian...

Dec 05, 2022 06:10 pm ET

Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the company’s partner Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company...

Nov 09, 2022 04:01 pm ET

Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the third quarter of 2022, along with recent product highlights and corporate...

Nov 08, 2022 08:30 am ET

Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present new data from its internal immuno-oncology pipeline at the upcoming Society for Immunotherapy of Cancer...

Nov 08, 2022 07:30 am ET

Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Dr. Peter Huang as its Chief Scientific Officer (CSO), effective immediately. Dr. Huang...

Oct 31, 2022 07:52 am ET

Zai Lab Announces Participation in November Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in November: Goldman...

Oct 18, 2022 07:30 am ET

Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the three months ended September 30,...

Oct 14, 2022 07:55 am ET

Zai Lab Launches its first Trust Report

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the launch of its 2022 Trust Report. Zai Lab recognizes the importance of building and maintaining trust...

Sep 27, 2022 08:00 am ET

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the first and only ADC approved in the U.S. for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or af

Sep 27, 2022 08:00 am ET

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global biopharmaceutical company, and Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies today announced an...

Sep 20, 2022 08:03 am ET

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meetin

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present a poster featuring initiation timing analysis from the Phase 3 PRIME study of ZEJULA® (niraparib) as...

Aug 23, 2022 07:30 am ET

Zai Lab Announces Participation in September Investor Conferences

Aug 09, 2022 04:05 pm ET

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the second quarter of 2022, along with recent product highlights and corporate...

Aug 08, 2022 07:02 am ET

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p5%) in the KarXT arm were all mild to moderate in severity and included constipation,...

Jul 19, 2022 07:38 am ET

Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022

Jul 17, 2022 08:00 pm ET

Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced, effective today, that its ordinary shares traded on The Stock Exchange of Hong Kong Limited (the “Hong Kong...

Jul 13, 2022 07:30 am ET

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License...

Jun 27, 2022 12:00 am ET

Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has completed its voluntary conversion of its secondary listing status to a primary listing on...

Jun 10, 2022 07:30 am ET

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted...

Jun 03, 2022 08:00 am ET

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that the EF-31 phase 2 pilot study, testing the safety and efficacy of Tumor Treating Fields (TTFields) together with standard-of-care (chemotherapy alone or in combination with trastuzumab for HER2-positive patients) as a first-line treatment in patients with gastric adenocarcinoma, met its primary endpoint of objective response rate with supportive signals

Jun 03, 2022 08:00 am ET

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Zai Lab (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced that the...

May 31, 2022 08:00 am ET

Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the presentation of a new subgroup data analysis from the Phase 3 PRIME study (NCT03709316) for niraparib...

May 24, 2022 07:30 am ET

Zai Lab Announces Upcoming Presentations at June Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following investor conferences in June: Jefferies...

May 20, 2022 04:01 pm ET

Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and the recent...

May 11, 2022 08:30 am ET

Thinking about buying stock in Veru, Embark Technology, Zai Lab, Ferroglobe PLC, or Desktop Metal?

NEW YORK, May 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERU, EMBK, ZLAB, GSM, and DM.

May 10, 2022 04:01 pm ET

Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the first quarter of 2022, along with recent product highlights and corporate...

May 05, 2022 11:54 am ET

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the company’s partner argenx (Euronext & Nasdaq: ARGX) reported positive data from the Phase 3 ADVANCE trial of VYVGART® (efgartigimod alfa-fcab). In adults with primary ITP,...

Apr 28, 2022 07:30 am ET

Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative,...

Apr 28, 2022 07:30 am ET

Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation...

Apr 21, 2022 07:30 am ET

Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that the Audit Committee of its Board of Directors has approved the engagement of KPMG as the Company’s...

Apr 20, 2022 07:30 am ET

Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022

Apr 19, 2022 08:00 am ET

Zai Lab Plants a Tree for Every Employee on Earth Day 2022

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today, in celebration of Earth Day 2022, a partnership with the global charity One Tree Planted, to plant one...

Apr 18, 2022 06:30 pm ET

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB

NEW YORK, April 18, 2022 /PRNewswire/ --

Apr 16, 2022 02:00 pm ET

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB

Apr 12, 2022 09:20 pm ET

Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List

SHANGHAI, April 12, 2022 /PRNewswire/ – Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists. Nisa Leung, Managing Partner of Qiming Venture Partners, and Duane Kuang, Founding Managing Partner of Qiming Venture Partners, ranked on the list.

Apr 06, 2022 08:01 am ET

Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present new data from its internal oncology discovery portfolio at the upcoming 2022 American Association for Cancer...

Apr 05, 2022 07:45 pm ET

ZLAB EQUITY NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB

Apr 04, 2022 04:20 pm ET

ZLAB INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB

NEW YORK , April 4, 2022 /PRNewswire/ --

Apr 04, 2022 10:56 am ET

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ:

Apr 03, 2022 06:46 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK, April 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Apr 01, 2022 03:03 pm ET

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ:

Mar 31, 2022 12:56 pm ET

EQUITY ALERT: Rosen Law Firm Encourages Zai Lab Limited Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ZLAB

Mar 30, 2022 09:35 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

Mar 26, 2022 12:45 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK, March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Mar 23, 2022 07:30 am ET

Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022

Mar 21, 2022 08:13 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

Mar 20, 2022 08:00 pm ET

Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today presented data from the Phase 3 PRIME study of ZEJULA (niraparib) as maintenance therapy at the Society of...

Mar 16, 2022 08:35 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK , March 16, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Mar 16, 2022 01:31 pm ET

(ZLAB) Alert: Did you Suffer a Substantial Loss? Contact Johnson Fistel About Leading ZLAB Class Action Lawsuit

Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), any of its executive officers, or others violated securities laws by misrepresenting or...

Mar 15, 2022 07:30 am ET

Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Josh Smiley as its Chief Operating Officer (COO). Mr. Smiley brings over 26 years of...

Mar 01, 2022 04:05 pm ET

Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the twelve months ended December 31, 2021, along with recent product highlights and...

Feb 17, 2022 07:30 am ET

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China

Feb 15, 2022 07:30 am ET

Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022

Feb 07, 2022 07:30 am ET

Zai Lab Announces Upcoming Presentation at February Investor Conference

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conference in February:...

Jan 12, 2022 07:30 am ET

Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 pivotal trial of Tumor...

Jan 06, 2022 07:30 am ET

Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application...

Dec 29, 2021 07:30 am ET

Zai Lab Announces Upcoming Presentations at January Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in January:...

Dec 22, 2021 07:30 am ET

Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer (CMO) to President...

Dec 17, 2021 06:09 pm ET

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that its partner argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving...

Dec 16, 2021 11:36 am ET

China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of...

Dec 16, 2021 04:43 am ET

China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABS

Dec 03, 2021 07:30 am ET

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer

Nov 30, 2021 07:30 am ET

Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Ca

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Phase 3 PRIME study of ZEJULA (niraparib) as maintenance therapy met its primary endpoint....

Nov 23, 2021 07:30 am ET

Zai Lab Announces Upcoming Presentations at December Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in...

Nov 22, 2021 07:30 am ET

Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that it has appointed Richard Gaynor, M.D., to its Board of Directors. Dr. Gaynor will also serve as...

Nov 16, 2021 07:30 am ET

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the first patient has been dosed in the Greater China portion of the global registrational ADHERE...

Nov 15, 2021 07:30 am ET

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the first patient has been treated in the Greater China portion of the global registrational Phase 3...

Nov 11, 2021 07:30 am ET

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), is a patient-focused, innovative, commercial-stage, global biopharmaceutical company. The company announced today that the first patient with primary immune thrombocytopenia (ITP) was treated with...

Nov 09, 2021 04:10 pm ET

Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the third quarter of 2021, along with recent product highlights and corporate...

Nov 09, 2021 08:00 am ET

Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Blueprint Medicines Corporation (NASDAQ:BPMC) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of...

Nov 09, 2021 07:37 am ET

PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), announced their entry into an exclusive license agreement for the development, manufactur

Nov 09, 2021 07:00 am ET

Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China

CAMBRIDGE, Mass. and SHANGHAI and SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China, including mainland China, Hong Kong, Macau and Taiwan. Discovered by Blueprint Medicines, BLU-945 and BLU-701 are investigational next-generation EGFR inhibitor

Nov 09, 2021 07:00 am ET

Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver...

Nov 04, 2021 07:30 am ET

Zai Lab Announces Upcoming Presentations in November Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in...

Oct 26, 2021 07:30 am ET

Zai Lab to Announce Third Quarter 2021 Financial Results

Oct 25, 2021 07:30 am ET

Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the first patient has been treated in the Greater China portion of the potentially registrational,...

Oct 21, 2021 03:00 am ET

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has reported positive topline results from a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept study of ZL-1102, an anti-IL-17A targeting Humabody®.

Oct 20, 2021 04:05 pm ET

ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced positive topline results from a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept...

Oct 19, 2021 09:00 am ET

Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and its partner Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on...

Oct 18, 2021 07:30 am ET

Zai Lab Appoints Scott Morrison to its Board of Directors

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has appointed Scott Morrison to its Board of Directors. Mr. Morrison will also serve as a member...

Oct 11, 2021 07:30 am ET

Zai Lab Announces Upcoming Presentations in October Investor Conferences

Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in October:...

Oct 05, 2021 07:30 am ET

Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that the bridging study of margetuximab plus chemotherapy in advanced, previously treated HER2+ breast cancer met its primary...

Oct 04, 2021 09:10 am ET

Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) partner Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug...

Ad blocking detected

Zai Lab Limited - American Depositary Shares (OQ:ZLAB)

Business Focus: N/A